Robust by Design: Addressing New Challenges in Bulk Drug Substance Management

Over 95% of all approved biologics and 90% of all vaccines are cold chain dependent. However, up to 25% of vaccines are believed to be lost due to cold chain failures. Modern cold chains should be supported by highly robust freezing solutions to meet new demands and help prevent losses.

This whitepaper discusses the philosophy of "robust by design” freezing containers based on characterization knowledge, design experience, and an understanding of real-world freezing applications.